Co-Authors
This is a "connection" page, showing publications co-authored by NATALIA LAPTEVA and CLIONA ROONEY.
Connection Strength
3.150
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.703
-
Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202.
Score: 0.543
-
Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32.
Score: 0.473
-
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43.
Score: 0.430
-
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
Score: 0.168
-
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343.
Score: 0.166
-
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5.
Score: 0.128
-
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
Score: 0.127
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.061
-
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
Score: 0.057
-
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113.
Score: 0.053
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.053
-
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
Score: 0.053
-
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
Score: 0.038
-
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362.
Score: 0.037
-
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7.
Score: 0.030
-
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
Score: 0.030